Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b.

Richert ND, Zierak MC, Bash CN, Lewis BK, McFarland HF, Frank JA.

Mult Scler. 2000 Apr;6(2):86-90.

PMID:
10773853
2.

Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis.

Richert ND, Ostuni JL, Bash CN, Leist TP, McFarland HF, Frank JA.

Mult Scler. 2001 Feb;7(1):49-58.

PMID:
11321194
3.

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.

Barbero P, Bergui M, Versino E, Ricci A, Zhong JJ, Ferrero B, Clerico M, Pipieri A, Verdun E, Giordano L, Durelli L; INCOMIN Trial Study Group.

Mult Scler. 2006 Feb;12(1):72-6. Erratum in: Mult Scler. 2006 Dec;12(6):830.

PMID:
16459722
4.
5.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T.

Clin Ther. 2008 Jun;30(6):1102-12. doi: 10.1016/j.clinthera.2008.06.013.

PMID:
18640466
6.
7.

Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients.

Frank JA, Richert N, Bash C, Stone L, Calabresi PA, Lewis B, Stone R, Howard T, McFarland HF.

Neurology. 2004 Mar 9;62(5):719-25.

PMID:
15007120
8.

Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.

Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X.

J Neurol. 2005 Jul;252(7):795-800. Epub 2005 Mar 18.

PMID:
15772741
10.

Methylprednisolone effect on brain volume and enhancing lesions in MS before and during IFNbeta-1b.

Rao AB, Richert N, Howard T, Lewis BK, Bash CN, McFarland HF, Frank JA.

Neurology. 2002 Sep 10;59(5):688-94.

PMID:
12221158
11.

Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.

Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD.

Neurology. 2009 Jun 9;72(23):1976-83. doi: 10.1212/01.wnl.0000345970.73354.17. Epub 2009 Mar 11.

PMID:
19279320
12.

Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.

Goldberg LD, Edwards NC, Fincher C, Doan QV, Al-Sabbagh A, Meletiche DM.

J Manag Care Pharm. 2009 Sep;15(7):543-55.

13.

Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis.

Gupta S, Solomon JM, Tasciyan TA, Cao MM, Stone RD, Ostuni JL, Ohayon JM, Muraro PA, Frank JA, Richert ND, McFarland HF, Bagnato F.

Mult Scler. 2005 Dec;11(6):658-68.

PMID:
16320725
14.

The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.

Durelli L, Barbero P, Bergui M, Versino E, Bassano MA, Verdun E, Ferrero B, Rivoiro C, Ferrero C, Picco E, Ripellino P, Viglietti D, Giuliani G, Montanari E, Clerico M; OPTIMS Study Group.

J Neurol. 2008 Sep;255(9):1315-23. doi: 10.1007/s00415-008-0879-6. Epub 2008 Sep 25.

PMID:
18825438
15.

Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.

Minagara A, Murray TJ; PROOF Study Investigators.

Curr Med Res Opin. 2008 Apr;24(4):1049-55. doi: 10.1185/030079908X280545 . Epub 2008 Feb 29.

PMID:
18315940
16.

Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.

La Mantia L, Di Pietrantonj C, Rovaris M, Rigon G, Frau S, Berardo F, Gandini A, Longobardi A, Weinstock-Guttman B, Vaona A.

Cochrane Database Syst Rev. 2014 Jul 26;(7):CD009333. doi: 10.1002/14651858.CD009333.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Nov 24;11:CD009333.

PMID:
25062935
17.

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.

Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM.

Neurology. 2009 Jun 9;72(23):1989-93. doi: 10.1212/WNL.0b013e3181a92b96.

18.

Early treatment and dose optimisation BENEFIT and BEYOND.

Hartung HP.

J Neurol. 2005 Sep;252 Suppl 3:iii44-iii50. Review.

PMID:
16170501
19.

MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.

Gasperini C, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C.

Mult Scler. 2002 Apr;8(2):119-23.

PMID:
11990868
20.

Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy.

Trojano M, Liguori M, Paolicelli D, Zimatore GB, De Robertis F, Avolio C, Giuliani F, Fuiani A, Livrea P; Southern Italy MS Group.

Mult Scler. 2003 Oct;9(5):451-7.

PMID:
14582768

Supplemental Content

Support Center